Apo-A1

Apo-A1

Apo-A1 Molekülinformation

Molecule Name
Apolipoprotein A-I
Molekülalias
Apolipoprotein A-I,APOA1,MGC117399
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Target-Alias
Epididymis Secretory Sperm Binding Protein,Apolipoprotein A-I(1-242),APOA1,ProapoA-I,Apo-AI,Apolipoprotein A1,Apo(A),ApoA-I,Apolipoprotein A-I,HPALP2
Molekülhintergrund
ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin.

Apo-A1 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ZerlasiranSLN-360Phase 2 ClinicalSilence Therapeutics Plc
Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Hyperlipidemias; Lipid Metabolism Disorders
Details
Fx-5AFx-5APhase 1 ClinicalKinemed Inc
Cardiovascular Diseases
Details
Recombinant NV-A01 adenovirusPhase 1 ClinicalNanjing Nuowei Biotechnology Co Ltd
Glioblastoma; Solid tumours
Details